The copper chelating agent triethylenetetramine (TRIEN) reduces bioavailability of Cu in breast cancer cells, thereby inhibiting AKT‐driven EMT (epithelial–mesenchymal transition) activation [46]. This evidence concerns the gene AKT1 and breast cancer.